产碳青霉烯酶肠杆菌科细菌的研究进展及治疗策略

doi:10.3969/j.issn.1673-8640.2016.07.018

检验医学 ›› 2016, Vol. 31 ›› Issue (7): 618-622.DOI: 10.3969/j.issn.1673-8640.2016.07.018

产碳青霉烯酶肠杆菌科细菌的研究进展及治疗策略

刘萍综述, 穆红审校

天津市第一中心医院检验科,天津 300192

收稿日期:2014-09-18 出版日期:2016-07-30 发布日期:2016-08-10
作者简介:null
作者简介：刘萍,女,1973年生,硕士,副主任技师,主要从事微生物检测和细菌耐药性研究。

通讯作者：穆红,联系电话： 022-23626123。
基金资助:
国家临床重点专科建设项目（检验专业）（2013-544）

Research progress and treatment strategies of carbapenemases-producing Enterobacteriaceae

LIU Ping, MU Hong

Department of Clinical Laboratory,Tianjin First Center Hospital,Tianjin 300192,China

Received:2014-09-18 Online:2016-07-30 Published:2016-08-10

摘要/Abstract

摘要：

近年来,耐碳青霉烯类抗菌药物的肠杆菌科细菌已在很多国家被发现,其主要耐药机制是产生碳青霉烯酶,特别是产A类肺炎克雷伯菌碳青霉烯酶（KPC）或依赖锌离子的B类金属酶（MβL）的肠杆菌科细菌在全球许多地区已出现暴发流行。产碳青霉烯酶肠杆菌科细菌（CPE）感染可导致患者死亡,但目前治疗方案非常有限,因此及早发现并监控CPE的定植或感染对控制细菌耐药性的出现和传播至关重要。

关键词: 肠杆菌科细菌, 碳青霉烯酶, β-内酰胺酶, 替加环素, 多黏菌素

Abstract:

Enterobacteriaceae being resistant to carbapenemases has occurred in many countries in recent years. The main mechanism is carbapenemases-producing. Particularly,Enterobacteriaceae,which produces Class A enzymes of Klebsiella pneumoniae carbapenemases（KPC） or Class B metallo-beta-lactamases（MβL）,has outbroken in many areas of the world. Carbapenemases-producing Enterobacteriaceae（CPE） could result in serious bacterial infections and lead to patient death. However,the current treatment options are limited,so the early detection and monitoring of CPE colonization or infection are crucial for controlling the occurrence and spread of drug resistance.

Key words: Enterobacteriaceae, Carbapenemases, Beta-lactamases, Tigecycline, Colistin

中图分类号:

R446.5

刘萍综述, 穆红审校. 产碳青霉烯酶肠杆菌科细菌的研究进展及治疗策略[J]. 检验医学, 2016, 31(7): 618-622.

LIU Ping, MU Hong. Research progress and treatment strategies of carbapenemases-producing Enterobacteriaceae[J]. Laboratory Medicine, 2016, 31(7): 618-622.

参考文献 22

1	JEON JH,LEE JH,LEE JJ,et al. Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance[J]. Int J Mol Sci,2015,16(5):9654-9692.
2	RODRGUEZ-BAO J,CISNEROS JM,GUDIOL C,et al. Treatment of infections caused by carbapenemase-producing Enterobacteriaceae[J]. Enferm Infecc Microbiol Clin,2014,32(Suppl 4):49-55.
3	BEN-DAVID D,KORDEVANI R,KELLER N,et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections[J]. Clin Microbiol Infect,2012,18(1):54-60.
4	TZOUVELEKIS LS,MARKOGIANNAKIS A,PSICHOGIOU M,et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae:an evolving crisis of global dimensions[J]. Clin Microbiol Rev,2012,25(4):682-707.
5	GARCÍA-SUREDA L,JUAN C,DOMÉNECH-SÁNCHEZ A,et al. Role of Klebsiella pneumoniae LamB Porin in antimicrobial resistance[J]. Antimicrob Agents Chemother,2011,55(4):1803-1805.
6	卜劲松,王勇. 耐碳青霉烯类药物鲍曼不动杆菌的碳青霉烯酶、整合酶基因型研究[J]. 检验医学,2015,30(6): 626-630.
7	MAVROIDI A,MIRIAGOU V,MALLI E,et al. Emergence of Escherichia coli sequence type 410(ST410) with KPC-2 β-lactamase[J]. Int J Antimicrob Agents,2012,39(3):247-250.
8	孙康德,陈旭,虞中敏,等. 碳青霉烯类耐药克雷伯菌属细菌的药物敏感性及同源性分析[J]. 检验医学,2014,29(11):1136-1140.
9	HALABY T,REULAND AE,AL NAIEMI N,et al. A case of New Delhi metallo-β-lactamase 1(NDM-1)-producing Klebsiella pneumoniae with putative secondary transmission from the Balkan region in the Netherlands[J]. Antimicrob Agents Chemother,2012,56(5):2790-2791.
10	NORDMANN P,COUARD JP,SANSOT D,et al. Emergence of an autochthonous and community-acquired NDM-1-producing Klebsiella pneumoniae in Europe[J]. Clin Infect Dis,2012,54(1):150-151.
11	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptility testing[S]. M100-S25,CLSI,2015.
12	RODRÍGUEZ-AVIAL C,RODRGUEZ-AVIAL I,MERINO P,et al. Klebsiella pneumoniae:development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient[J]. Clin Microbiol Infect,2012,18(1):61-66.
13	BRATU S,TOLANEY P,KARUMUDI U,et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn,NY:molecular epidemiology and in vitro activity of polymyxin B and other agents[J]. J Antimicrob Chemother,2005,56(1):128-132.
14	POURNARAS S,VRIONI G,NEOU E,et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase(KPC)-producing Enterobacteriaceae strains by time-kill assay[J]. Int J Antimicrob Agents,2011,37(3):244-247.
15	SOULI M,GALANI I,BOUKOVALAS S,et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development[J]. Antimicrob Agents Chemother,2011,55(5):2395-2397.
16	SAMONIS G,MARAKI S,KARA-GEORGOPOULOS DE,et al. Synergy of fosfomycin with carbapenems,colistin,netilmicin,and tigecycline against multidrug-resistant Klebsiella pneumoniae,Escherichia coli,and Pseudomonas aeruginosa clinical isolates[J]. Eur J Clin Microbiol Infect Dis,2012,31(5):695-701.
17	PATEL N,HARRINGTON S,DIHMESS A,et al. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae[J]. J Antimicrob Chemother,2011,66(7):1600-1608.
18	BULIK CC,TESSIER PR,KEEL RA,et al. In vivo comparison of CXA-101(FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms[J]. Antimicrob Agents Chemother,2012,56(1):544-549.
19	ZUCKERMAN T,BENYAMINI N,SPRECHER H,et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state[J]. Bone Marrow Transplant,2011,46(9):1226-1230.
20	MARTNEZ-MARTNEZ L,GONZLEZ-LPEZ JJ. Carbapenemases in Enterobacteriaceae:types and molecular epidemiology[J]. Enferm Infecc Microbiol Clin,2014,32(Suppl 4):4-9.
21	TNGDN T ,GISKE CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae:clinical perspectives on detection,treatment and infection control[J]. J Intern Med,2015,277(5):501-512.
22	NORDMANN P.Carbapenemase-producing Enterobacteriaceae:overview of a major public health challenge[J]. Med Mal Infect,2014,44(2):51-56.

[1]	徐琪, 潘芬, 孙燕, 石迎迎, 于方圆, 张泓. 肠道定植CRE筛查技术方法学评价[J]. 检验医学, 2022, 37(8): 761-765.
[2]	孙英, 李轶, 闫文娟, 荆楠, 马冰. 河南地区少见CRE耐药性分析及碳青霉烯酶初筛实验的临床应用[J]. 检验医学, 2022, 37(2): 146-149.
[3]	王芳, 邓燕燕, 林见敏, 王金金, 龚倩, 黄声雷. 改良碳青霉烯灭活试验和碳青霉烯酶抑制剂增强试验鉴定肠杆菌目细菌产碳青霉烯酶型别的临床价值[J]. 检验医学, 2022, 37(12): 1183-1186.
[4]	包海林, 花鸿燕, 孙恒亮, 刘华, 吉顺年, 秦陈浩, 杜鸿. 改良Carba Np试验和mCIM/eCIM快速鉴定产碳青霉烯酶肠杆菌科细菌表型的临床应用[J]. 检验医学, 2022, 37(10): 963-968.
[5]	姚锂凤, 郑巧平, 杨蒙, 罗清琼, 陈旭, 陈福祥. 胶体金免疫层析法快速检测CRE碳青霉烯酶效果评价[J]. 检验医学, 2022, 37(1): 68-71.
[6]	尹娟, 王莹超, 眭阳, 江春, 时蕴琦, 朱超望. mCIM与eCIM在产碳青霉烯酶肠杆菌科细菌表型筛查中的价值[J]. 检验医学, 2021, 36(2): 177-180.
[7]	杨红梅, 陶建敏, 魏甜, 王蒋君, 毛嘉宏, 王海英. 2015—2019年上海某中西医结合医院住院患者碳青霉烯类耐药肠杆菌科细菌耐药性分析[J]. 检验医学, 2021, 36(1): 87-91.
[8]	陆书华, 李晓哲, 刘凌云, 金呈强, 戈宁宁, 董海新. 山东某院耐碳青霉烯类肠杆菌科细菌临床感染特征及耐药基因分析[J]. 检验医学, 2020, 35(8): 757-762.
[9]	钟峰, 冯艺, 张晶晶, 许岩, 方咏梅, 陶秀彬, 吴竞. 替加环素联合亚胺培南对黏液型铜绿假单胞菌的体外抗菌活性及生物膜抑制作用分析[J]. 检验医学, 2020, 35(6): 519-523.
[10]	刘存芬, 王燕, 杨溶, 胡丽香. 200株血流感染大肠埃希菌耐药性分析[J]. 检验医学, 2020, 35(12): 1263-1266.
[11]	周宏伟, 胡燕燕, 张嵘. 碳青霉烯类耐药肠杆菌科细菌的检测方法[J]. 检验医学, 2020, 35(10): 971-973.
[12]	邹成韵, 杨红梅, 王海英. 碳青霉烯类耐药肠杆菌科细菌去定植策略研究现状[J]. 检验医学, 2020, 35(10): 974-978.
[13]	李世荣, 林怡菁, 蒋晓飞, 关明. 双浓度联合改良碳青霉烯灭活试验筛查CRE的临床应用价值[J]. 检验医学, 2020, 35(10): 979-982.
[14]	何丽华, 倪丽君, 杨思敏, 羽晓瑜, 周爱萍, 胡靓, 郭建, 吴文娟. RT-PCR快速检测产KPC型碳青霉烯酶肺炎克雷伯菌临床应用评价[J]. 检验医学, 2020, 35(10): 983-987.
[15]	唐瑜, 沈平华, 史保庆, 蒋晓飞. Polymyxin NP实验筛查肠杆菌科多黏菌素耐药菌株临床评价[J]. 检验医学, 2020, 35(10): 994-999.

产碳青霉烯酶肠杆菌科细菌的研究进展及治疗策略

Research progress and treatment strategies of carbapenemases-producing Enterobacteriaceae

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 22

相关文章 15

编辑推荐

Metrics